Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amphastar Pharma
(NQ:
AMPH
)
46.87
+0.85 (+1.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amphastar Pharma
< Previous
1
2
3
4
5
Next >
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92
June 30, 2022
Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92.
Via
Investor's Business Daily
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
June 28, 2022
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before.
Via
Investor's Business Daily
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade
June 15, 2022
Day One Biopharmaceuticals stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 83 to 92.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Intraday Session
June 09, 2022
Via
Benzinga
36 Stocks Moving In Thursday's Mid-Day Session
June 09, 2022
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) jumped 65% to $0.6382.
Via
Benzinga
Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval
April 08, 2022
Via
Benzinga
69 Biggest Movers From Yesterday
June 10, 2022
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday.
Via
Benzinga
Amphastar Pharmaceuticals's Return On Capital Employed Insights
June 02, 2022
Pulled from Benzinga Pro data, Amphastar Pharmaceuticals (NASDAQ:AMPH) posted Q1 earnings of $24.25 million, an increase from Q4 of 22.74%. Sales dropped to $120.37 million, a 0.43% decrease between...
Via
Benzinga
Earnings Scheduled For March 10, 2022
March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...
Via
Benzinga
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot'
May 24, 2022
United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier.
Via
Investor's Business Daily
7 Safe Small-Cap Stocks to Buy Now
May 12, 2022
If you're looking for resilient plays with high upside potential, consider these seven safe small-cap stocks to buy.
Via
InvestorPlace
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
May 11, 2022
Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97.
Via
Investor's Business Daily
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
April 14, 2022
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
April 12, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
10 Stocks That Have Moved Over 20% Since The Indices Plummeted
April 08, 2022
The start of 2022 saw a decline in the stock market. For seasoned investors, this was not unexpected, as corrections in the market are commonplace from January through to March.
Via
Benzinga
Why Top-Rated IBD 50 Stock Amphastar Pharmaceuticals Added To Its 75% Run
April 08, 2022
FDA action just sent this red-hot biotech stock to a high, continuing its strong run.
Via
Investor's Business Daily
Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating
April 07, 2022
On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier.
Via
Investor's Business Daily
Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92
April 07, 2022
On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92.
Via
Investor's Business Daily
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
April 04, 2022
Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91.
Via
Investor's Business Daily
Stocks That Hit 52-Week Highs On Thursday
April 07, 2022
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...
Via
Benzinga
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating
March 25, 2022
Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91.
Via
Investor's Business Daily
Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating
March 23, 2022
Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday.
Via
Investor's Business Daily
7 “A”-Rated Stocks to Ground Your Portfolio
March 17, 2022
It's a good time to make sure you have "A"-rated stocks in your portfolio. Many of the ones here have my triple-"A" rating.
Via
InvestorPlace
Amphastar Pharmaceuticals: Q4 Earnings Insights
March 10, 2022
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Earnings Preview For Amphastar Pharmaceuticals
March 09, 2022
Amphastar Pharmaceuticals (NASDAQ:AMPH) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....
Via
Benzinga
Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade
February 14, 2022
Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...
Via
Benzinga
7 Safe Stocks to Rely On When the Market Swerves
February 09, 2022
When markets that have flown so high for so long start to tumble, along with an economy that transitioning, safe stocks are essential.
Via
InvestorPlace
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
February 07, 2022
The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79.
Via
Investor's Business Daily
Top Russell 2000 Stocks: Trading Opportunities For Next Week
February 06, 2022
A security pattern traces the distinct movements of security prices that, once recognized, helps traders to make informed trading decisions. Let's look at some Russell 2000 stock opportunities by...
Via
Talk Markets
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.